IL10 and breast carcinoma: Moreover, systemic administration of pegylated IL-10 (PEG-IL-10), a long-lived form of recombinant IL-10, succeeded to induce CD8+ T-cell–mediated tumor rejection across different murine tumor models, such as transplanted models of PDV6 squamous cell carcinoma, breast carcinoma, and melanoma, as well as chemically induced skin tumors [51,52,53].